newsfilter
← Latest News
GlobeNewswire·

Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI

ACHFF
  • Arch Biopartners Inc. announced that Royal Columbian Hospital has begun patient recruitment for its Phase II trial evaluating LSALT peptide to prevent acute kidney injury in on-pump cardiac surgery patients.
  • Royal Columbian Hospital is the ninth global site activated for the CS-AKI study & the fourth Canadian site to recruit, joining active dosing locations at Toronto General Hospital, St. Michael's Hospital, & the University of Calgary.
  • The company is conducting feasibility discussions with additional cardiac surgery centers in Canada & the United States, including three prospective U.S. sites & one new Ontario site.
  • The international, multi-center CS-AKI Phase II trial targets 240 patients to evaluate LSALT peptide's ability to reduce acute kidney injury rates within seven days post-surgery per KDIGO criteria.
  • The Board granted 150,000 stock options to a new director at $1.05 per share, exercisable for 10 years starting April 29, 2026, as remuneration for the period ending March 30, 2027.
  • Arch Biopartners continues to advance its pipeline, including the LSALT peptide Phase II trial, the Cilastatin repurposed drug Phase II trial for toxin-induced AKI, & a CKD platform targeting chronic kidney disease.
  • The company reported 67,933,289 common shares outstanding as of April 30, 2026.